[go: up one dir, main page]

TWI255720B - Novel preparation and administration form comprising an acid-labile active compound and process for production thereof - Google Patents

Novel preparation and administration form comprising an acid-labile active compound and process for production thereof

Info

Publication number
TWI255720B
TWI255720B TW089111052A TW89111052A TWI255720B TW I255720 B TWI255720 B TW I255720B TW 089111052 A TW089111052 A TW 089111052A TW 89111052 A TW89111052 A TW 89111052A TW I255720 B TWI255720 B TW I255720B
Authority
TW
Taiwan
Prior art keywords
active compound
acid
production
administration form
novel preparation
Prior art date
Application number
TW089111052A
Other languages
Chinese (zh)
Inventor
Rango Dietrich
Udolf Linder
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI255720(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of TWI255720B publication Critical patent/TWI255720B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Novel administration forms and preparations for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in a matrix made of a mixture of a triglyceride and at least one solid paraffin or in a matrix made of a mixture comprising at least one fatty acid ester and at least one solid paraffin. In particular, the active compound units are microspheres which can be produced by prilling.
TW089111052A 1999-06-07 2000-06-07 Novel preparation and administration form comprising an acid-labile active compound and process for production thereof TWI255720B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19925710A DE19925710C2 (en) 1999-06-07 1999-06-07 New preparation and dosage form containing an acid labile proton pump inhibitor

Publications (1)

Publication Number Publication Date
TWI255720B true TWI255720B (en) 2006-06-01

Family

ID=7910295

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089111052A TWI255720B (en) 1999-06-07 2000-06-07 Novel preparation and administration form comprising an acid-labile active compound and process for production thereof

Country Status (6)

Country Link
AR (1) AR024310A1 (en)
CO (1) CO5160296A1 (en)
DE (1) DE19925710C2 (en)
MY (1) MY138975A (en)
PE (1) PE20010303A1 (en)
TW (1) TWI255720B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375269T3 (en) * 2000-12-07 2012-02-28 Nycomed Gmbh PHARMACEUTICAL PREPARATION IN THE FORM OF A PASTE THAT INCLUDES A LI? BIL ACTIVE ACTIVE INGREDIENT BEFORE THE �? CIDOS.
DE10061138C1 (en) * 2000-12-07 2002-08-14 Byk Gulden Lomberg Chem Fab Pharmaceutical preparation in the form of a juice containing an acid-labile active ingredient
DE10061137B4 (en) * 2000-12-07 2016-10-06 Takeda Gmbh New pharmaceutical preparation
DE10061136C1 (en) * 2000-12-07 2002-10-24 Byk Gulden Lomberg Chem Fab Stable, rapidly disintegrating tablets containing proton pump inhibitors, useful for treating elevated gastric secretion, comprising multiple drug units and auxiliaries including basic filler
UA80393C2 (en) * 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
AU2002234545A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
DE10061135C1 (en) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Stable gel preparation for oral administration of acid-labile drug, especially proton pump inhibitor, comprises multiple drug units dispersed in gel base
EP1341528B1 (en) * 2000-12-07 2012-01-18 Nycomed GmbH Rapidly disintegrating tablet comprising an acid-labile active ingredient
SE0101379D0 (en) 2001-04-18 2001-04-18 Diabact Ab Composition that inhibits gastric acid secretion
CA2461653A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Edible composition and dosage form comprising an edible shell
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
MXPA05000301A (en) * 2002-07-03 2005-03-31 Abbott Lab Liquid dosage forms of proton pump inhibitors.
DE10244129B4 (en) * 2002-09-23 2006-04-20 Iongate Biosciences Gmbh H + -K + -ATPase assay
SE0203065D0 (en) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
HRP20050399B1 (en) 2003-03-10 2013-09-30 Takeda Gmbh Novel process for the preparation of roflumilast
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725924C3 (en) * 1977-06-08 1980-11-06 Hobeg Hochtemperaturreaktor-Brennelement Gmbh, 6450 Hanau Process for the production of spherical particles from low-melting organic substances
DE3524572A1 (en) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K SOLID PHARMACEUTICAL FORMS FOR PERORAL USE CONTAINING 9-DEOXO-11-DEOXY-9,11- (IMINO (2- (2-METHOXYETHOXY) ETHYLIDEN) -OXY) - (9S) -ERYTHROMYCIN AND METHOD FOR THE PRODUCTION THEREOF
JP2681373B2 (en) * 1988-07-18 1997-11-26 塩野義製薬株式会社 Method for manufacturing sustained-release preparation

Also Published As

Publication number Publication date
AR024310A1 (en) 2002-09-25
DE19925710A1 (en) 2000-12-14
MY138975A (en) 2009-08-28
PE20010303A1 (en) 2001-03-09
CO5160296A1 (en) 2002-05-30
DE19925710C2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
UA74339C2 (en) Dosage form of proton pump inhibitor representing individual matrix-included units and method for its manufacture
TWI255720B (en) Novel preparation and administration form comprising an acid-labile active compound and process for production thereof
PT100234A (en) New bicyclic and tricyclic amino acid esters, process for their preparation
IL155964A0 (en) A pharmaceutical composition comprising an active ingredient uniformly dispersed in a matrix
EP0727216A4 (en) Medicinal composition containing sialic acid derivative
GR890100467A (en) METHOD FOR THE MANUFACTURE OF INTERESTING PHARMACEUTICAL COMPOSITION.
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
GR3017411T3 (en) Production process of microspheres.
MY111841A (en) Injectable liposomal pharmaceutical preparations
MY143793A (en) Non-tabletted, chewable, individually dosed administration forms
DE69521525D1 (en) LIGNANE, METHOD FOR THE PRODUCTION THEREOF, THEIR PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS
HU169967B (en) Insecticide and acaricide compositions and process for producing pyrimidine-thionothiol-phosphoric acid esters as active components
JPS52806A (en) Preparation of ester
PT77984A (en) Process for the preparation of detergent compositions with dialquil-sulphosuccinate
HUT39752A (en) Insecticide, acaricide, and nematocide compositions containing pyridyl-thiono-phosphoric acid esters as active ingredients and process for preparing the active ingredient
ES2168351T3 (en) PHARMACEUTICAL PREPARATIONS CONTAINING NIFEDIPINE AND PROCEDURE FOR PREPARATION.
CA2017155A1 (en) Method for transplantation of fertilized ova
HUT54660A (en) Process for producing new cyclic anthranilic acid-carboxylic acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
BG100669A (en) Medicamentous form and method for its preparation

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees